Stock listing

Hamburg:PSH0 Sernova Biotherapeutics Inc Aktie

German listing (Hamburg) of Sernova Biotherapeutics Inc · home listing TSX:SVA

Follow Sernova Biotherapeutics Inc into a list and get an email when it puts out news.

Home listing price · TSX:SVA

$0.09 CAD -0.01 (-10.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSX:SVA

Past year -35.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.09 – $0.095 CADNov 20, 2026
Volume
343,510 sharesNov 20, 2026
Market cap
$33.99M CADAt the close on Nov 20, 2026 · price × 377.6M shares outstanding
52-week range
$0.09 – $0.20 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$23,311 CADMedian day 75,350 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sernova Biotherapeutics Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSX:SVA · Home$0.09 CAD-0.01 (-10.0%)343,510$0.09$0.095$0.09$0.10Close on Nov 20, 2026
OTC:SEOVF$0.067 USD0.000 (0.0%)429$0.067$0.067$0.067$0.067Close on Nov 20, 2026
Xetra:PSH0€0.064 EUR+0.005 (+8.4%)1,196€0.059€0.068€0.059€0.059Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:SVA · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.09-0.01-10.0%$0.09$0.095$0.09343,510
$0.100.000.0%$0.10$0.10$0.09300,727
$0.10-0.005-4.8%$0.11$0.115$0.10303,582
$0.105-0.005-4.5%$0.10$0.105$0.10111,297
$0.11+0.005+4.8%$0.11$0.11$0.116,310
$0.105-0.005-4.5%$0.115$0.115$0.10102,090
$0.110.000.0%$0.11$0.115$0.1142,611
$0.110.000.0%$0.11$0.115$0.1122,500
$0.110.000.0%$0.11$0.12$0.1158,555
$0.11+0.005+4.8%$0.105$0.11$0.10532,010
$0.1050.000.0%$0.105$0.11$0.10512,124
$0.105-0.01-8.7%$0.11$0.11$0.10598,115
$0.115+0.015+15.0%$0.105$0.12$0.10149,829
$0.10-0.005-4.8%$0.105$0.105$0.1039,444
$0.105-0.005-4.5%$0.105$0.105$0.10547,270
$0.110.000.0%$0.105$0.11$0.10526,455
$0.110.000.0%$0.11$0.11$0.112,367
$0.110.000.0%$0.11$0.11$0.10529,778
$0.110.000.0%$0.105$0.11$0.10570,630
$0.110.000.0%$0.115$0.115$0.1137,444
$0.11-0.01-8.3%$0.12$0.12$0.1167,500
$0.12+0.01+9.1%$0.11$0.12$0.1198,400
$0.11-0.01-8.3%$0.12$0.12$0.1190,000
$0.120.000.0%$0.12$0.12$0.1234,900
$0.120.000.0%$0.12$0.12$0.12167,000
$0.120.000.0%$0.11$0.12$0.1115,800
$0.12+0.01+9.1%$0.12$0.12$0.11130,200
$0.11-0.01-8.3%$0.11$0.12$0.1133,800
$0.120.000.0%$0.12$0.12$0.1216,400
$0.120.000.0%$0.12$0.12$0.1142,600
$0.120.000.0%$0.12$0.12$0.1273,700
$0.12+0.01+9.1%$0.11$0.12$0.11266,900
$0.110.000.0%$0.11$0.13$0.11384,700
$0.110.000.0%$0.12$0.12$0.1165,700
$0.110.000.0%$0.11$0.12$0.1137,300
$0.11+0.02+22.2%$0.10$0.12$0.101,433,900
$0.090.000.0%$0.09$0.09$0.09274,200
$0.090.000.0%$0.09$0.10$0.09284,200
$0.090.000.0%$0.10$0.10$0.0977,000
$0.09-0.01-10.0%$0.10$0.10$0.09721,200
$0.100.000.0%$0.10$0.11$0.10455,400
$0.10-0.01-9.1%$0.10$0.11$0.10156,900
$0.110.000.0%$0.11$0.11$0.10264,600
$0.110.000.0%$0.11$0.11$0.10257,400
$0.110.000.0%$0.11$0.11$0.11163,800
$0.11+0.01+10.0%$0.11$0.11$0.10199,000
$0.10-0.01-9.1%$0.11$0.12$0.10983,200
$0.11-0.03-21.4%$0.14$0.14$0.111,227,000
$0.140.000.0%$0.14$0.15$0.14547,500
$0.140.000.0%$0.15$0.15$0.14500,900
$0.14+0.01+7.7%$0.15$0.15$0.14350,500
$0.13+0.02+18.2%$0.12$0.15$0.101,440,900
$0.11-0.01-8.3%$0.12$0.12$0.1165,300
$0.120.000.0%$0.11$0.12$0.1137,000
$0.12+0.01+9.1%$0.11$0.12$0.115,000
$0.110.000.0%$0.11$0.11$0.11112,500
$0.110.000.0%$0.12$0.12$0.1140,800
$0.110.000.0%$0.12$0.12$0.1171,700
$0.110.000.0%$0.11$0.12$0.1151,500
$0.110.000.0%$0.12$0.12$0.114,000
$0.110.000.0%$0.115$0.115$0.10568,110
$0.110.000.0%$0.115$0.115$0.1140,202
$0.110.000.0%$0.11$0.11$0.11121,600
$0.110.000.0%$0.11$0.11$0.1144,400

Splits

1 split · TSX:SVA · every price before a split is adjusted for it

DayRatioWhat
1-for-3Consolidation
Ticker
Hamburg:PSH0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hamburg
Currency
EUR

What changed lately

Latest news

2026 Q1 MD&A

Mar 16, 2026

Closed $0.16 (-5.9%) on Mar 16, 2026

All Sernova Biotherapeutics Inc news

Sernova Biotherapeutics Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 165 in all · newest Oct 19, 2026 · oldest 2015
Decks
29 decks · latest 2026

Where Sernova Biotherapeutics Inc is listed

ListingExchangeCountryCurrency
TSX:SVA · Home listingTSXCanadaCAD
OTC:SEOVFOTCUnited StatesUSD
Xetra:PSH0XetraGermanyEUR
Tradegate:PSH0TradegateGermanyEUR
gettex:PSH0gettexGermanyEUR
Cboe Canada:SVACboe CanadaCanadaCAD
LS Exchange:A411DWLS ExchangeGermanyEUR
Lang & Schwarz:A411DWLang & SchwarzGermanyEUR
Munich:PSH0MunichGermanyEUR
Dusseldorf:PSH0DusseldorfGermanyEUR
Hamburg:PSH0 · This pageHamburgGermanyEUR
Stuttgart:PSH0StuttgartGermanyEUR
Frankfurt:PSH0FrankfurtGermanyEUR
Hanover:PSH0HanoverGermanyEUR

Valuation

Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
$36.51M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
0.40

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sernova Biotherapeutics Inc · TSX:SVAUS$23.70MUS$25.46Mn/an/an/an/an/an/a0.40
Original Biomedicals Co Ltd · TPEX:6483US$23.81MUS$21.67Mn/a1,875×n/a7.1×n/a0.0×n/a
Scynexis, Inc. · NASDAQ:SCYXUS$23.69M−US$21.66Mn/a−1.1×n/a0.4×−53.5%0.0×1.76
ImmuPharma plc · LSE:IMMUS$23.68MUS$22.77Mn/an/an/a9.9×n/a0.0×n/a
Organoidsciences Ltd. · KRX:476040US$23.46MUS$6.52Mn/a3.8×n/a1.1×−814.8%0.4×n/a
Immutep Ltd · ASX:IMMUS$23.41M−US$24.93Mn/a−2.6×n/a0.6×−544.8%0.0×n/a
ABVC BioPharma, Inc. · NASDAQ:ABVCUS$23.37MUS$25.81Mn/an/an/a1.8×n/a0.2×1.39
Incannex Healthcare Inc. · NASDAQ:IXHLUS$23.33M−US$44.85Mn/an/an/a0.3×n/a0.0×0.98
Actinogen Medical Limited · ASX:ACWUS$23.08MUS$15.17Mn/an/an/a1.6×n/a0.2×n/a
BioNxt Solutions Inc · CSE:BNXTUS$22.78MUS$22.72Mn/an/an/an/an/an/a0.22
Polyrizon Ltd. · NASDAQ:PLRZUS$22.61MUS$7.56Mn/an/an/a0.9×n/a0.0×0.67
Median of the othersUS$23.39MUS$11.37M1.4×1.1×−544.8%0.0×0.98

Forecasts

Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
1.00 CAD · Analysts' mean
EPS, year to Oct 2026
-0.025 · 2 analysts

Team and board

Officers

OfficerRole
Jonathan RigbyChief Executive Officer
James ParsonsChief Financial Officer
David BurkeVice President, Investor Relations
Marie KaldchibachiDirector, Finance
Marylyn RigbyChief Communications Officer
Patricia BeastonChief Medical Officer

Board

DirectorRole
John L. BrooksChair
Bernd MuehlenwegDirector
David PatersonDirector
Jonathan RigbyChief Executive Officer
Steven SanghaDirector
Tanya LewisDirector

Events

Next results
Dec 17, 2026 (expected)
QuarterResultsShare move
Q3 2026Sep 10, 2026 · After close0.0%
Q2 2026Jun 11, 2026 · After close−6.3%
Q1 2026Mar 13, 2026 · After close−5.9%
Q4 2025Dec 19, 2025 · After close+7.7%
Q3 2025Sep 15, 2025 · After close0.0%
Q2 2025Jun 13, 2025 · After close−5.9%
Q1 2025Mar 14, 2025 · After close+5.6%
Q4 2024Dec 23, 2024 · After close0.0%
Q3 2024Sep 16, 2024 · After close0.0%
Q2 2024Jun 14, 2024 · After close−8.8%
All 19 quarters
QuarterResultsShare move
Q1 2024Mar 18, 2024 · After close−5.0%
Q4 2023Jan 29, 2024 · Before open−3.1%
Q3 2023Sep 12, 2023 · After close+1.3%
Q2 2023Jun 13, 2023 · After close−3.3%
Q1 2023Mar 16, 2023 · After close−1.1%
Q4 2022Jan 27, 2023+1.7%
Q3 2022Sep 14, 2022 · After close+6.2%
Q2 2022Jun 27, 2022 · After close−6.7%
Q1 2022Feb 13, 2022 · After close−5.1%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (2026)Merger or acquisition16 slides2026
Investor Presentation (February 2025)Investor deck24 slidesFebruary 2025
Investor Presentation (December 2024)Investor deck31 slidesDecember 2024
Investor Presentation (September 2024)Investor deck21 slidesSep 12, 2024
Investor Presentation (March 2024)Investor deck32 slidesMarch 2024
Sernova — Investor Presentation (September 2023)Investor deck27 slidesSeptember 2023
Sernova — Investor Presentation (May 2023)Investor deck21 slidesMay 2023
Sernova — Shareholder Meeting (April 2023)Shareholder meeting17 slidesApr 27, 2023
Technical Presentation (April 2023)Technical10 slidesApr 24, 2023
Sernova — Investor Presentation (January 2023)Investor deck27 slidesJanuary 2023
All 29 decks
DeckKindSlidesDate
Sernova — Investor Presentation (January 2023)Investor deck27 slidesJanuary 2023
Sernova — Investor Presentation (November 2022)Investor deck27 slidesNovember 2022
Sernova — Investor Presentation (August 2022)Investor deck34 slidesAugust 2022
Sernova — Investor Presentation (March 2022)Investor deck26 slidesMarch 2022
Sernova — Investor Presentation (February 2022)Investor deck25 slidesFebruary 2022
Sernova — Investor Presentation (January 2022)Investor deck33 slidesJanuary 2022
Sernova — Investor Presentation (November 2021)Investor deck32 slidesNovember 2021
Sernova — Investor Presentation (November 2021)Investor deck31 slidesNovember 2021
Sernova — Investor Presentation (January 2021)Investor deck31 slidesJanuary 2021
Sernova — BIOInvestor Forum 2020Conference26 slidesOctober 2020
Sernova — Cell and Gene Meeting on the Mesa 2020Conference26 slidesOctober 2020
Sernova — Investor Presentation (May 2020)Investor deck33 slidesMay 2020
Sernova — Bloom Burton Healthcare Investor Conference 2019Conference35 slidesMay 1, 2019
Sernova — Investor Presentation (August 2018)Investor deck23 slidesAugust 2018
Sernova — Investor Presentation (2016)Investor deck37 slidesOct 29, 2016
Sernova — Investor Presentation (2015)Investor deck25 slidesSep 5, 2015
Sernova — Investor Presentation (2015)Investor deck19 slides2015
Sernova — Investor Presentation (2014)Investor deck22 slides2014
Sernova — Investor Presentation (2013)Investor deck22 slidesDec 27, 2013

Open Decks

Financings

RaiseDateIn US dollars
Convertible notes and common stock purchase warrants of Seraxis
Closed: US$11.2M raised
Buyers: Dr. Steven Sangha / Arlo Investments; Jonathan Rigby; Will Rust
Insiders: Insiders participated, including Dr. Steven Sangha / Arlo Investments, Sernova management and Seraxis management
Use of proceeds: cGMP manufacturing of SR-02 islet cells and enrollment of T1D patients for the Phase 1/2 clinical trial
Oct 5, 2026
Unsecured convertible debentures
Closed: C$1.5M raised · C$0.15 · Warrants at C$0.25 for 36 months
Insiders: Financing made with an insider; insiders participated, treated as related party transactions
Apr 23, 2026US$1.1M
Private placement of units
Closed: C$4M raised
Insiders: Unit financing made with an insider; insiders participated, treated as related party transactions
Use of proceeds: To retire outstanding loan obligations
Apr 23, 2026US$2.92M
Private placement of units
Update: C$4M · C$0.15 a unit · 1 warrant at C$0.2 for 36 months
Insiders: Shareholders approved the issuance of the units to an insider of the Company
Use of proceeds: Retire the existing $4.0 million secured term loan maturing April 16, 2026
Apr 9, 2026US$2.93M
Private placement of units
Announced: C$1.6M · C$0.15 a unit · 1 warrant at C$0.25 for 36 months
Mar 4, 2026US$1.17M
Private placement of units
Tranche closed: C$874,600 raised · C$0.16 a unit · 1 warrant at C$0.4 for 36 months
Use of proceeds: General operating capital and launch of final Cohort C in the Phase 1/2 trial of its Cell Pouch Bio-hybrid Organ for type 1 diabetes
Nov 13, 2025US$623,912
Unsecured convertible debenture
Closed: C$1M raised · Warrants at C$0.2
Buyers: Dr. Steven Sangha (CAD$1,000,000 unsecured convertible debenture and 5,000,000 warrants)
Insiders: The debenture and warrants were issued to Dr. Steven Sangha, a shareholder and board member; a related party transaction under MI 61-101
Use of proceeds: Working capital
Mar 5, 2025US$695,894

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue342.6K540.3K445.6K440.0K267.2K225.2K61.5K64.5K39.9K7.56K
Gross profit-342.6K-540.3K-445.6K-440.0K-267.2K-225.2K-61.5K-64.5K-39.9K-7.56K
Research and development7.28M22.4M32.3M16.9M4.64M2.76M2.01M2.23M1.54M1.20M
Selling, general and administrative7.50M8.97M8.46M7.83M2.29M2.48M2.00M1.47M1.10M1.30M
Operating income-15.1M-31.8M-41.1M-24.2M-6.87M-5.22M-3.97M-3.69M-2.63M-2.49M
Depreciation and amortization342.6K540.3K445.6K440.0K267.2K225.2K61.5K64.5K39.9K7.56K
EBITDA-14.8M-31.3M-40.7M-23.7M-6.60M-5.00M-3.91M-3.62M-2.59M-2.48M
Interest expense754.8K586.9K32.1K118.0K58.4K86.3K7.27K9.71K13.8K9.69K
Income before tax-15.8M-32.2M-39.6M-24.4M-6.97M-5.32M-3.97M-3.70M-2.64M-2.50M
Income tax-92.2K7.00K-629.0K118.0K58.4K86.3K7.27K9.71K13.8K9.69K
Net income-15.7M-32.2M-39.0M-24.5M-7.02M-5.41M-3.98M-3.70M-2.64M-2.50M
Earnings per share, basic-0.05-0.10-0.13-0.09-0.03-0.03-0.02-0.02-0.02-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents265.0K6.01M8.72M3.78M27.9M3.95M1.80M1.74M2.63M5.20M
Short-term investments011.1M46.0M002.01M1.00M1.00M700.0K
Receivables122.6K298.1K1.05M1.15M448.9K506.8K735.0K471.6K641.4K231.4K
Current assets522.6K6.47M21.0M51.1M28.3M4.61M5.32M3.32M4.31M6.20M
Property, plant and equipment17.7K833.9K507.4K653.7K564.7K203.4K251.5K289.0K238.5K26.6K
Goodwill316.4K
Total assets764.2K7.53M22.1M52.5M29.8M5.73M5.57M3.61M4.55M6.23M
Accounts payable17.7M17.2M6.85M3.61M379.5K529.4K472.9K182.6K182.9K116.0K
Current liabilities24.8M20.0M9.59M4.74M1.48M878.1K686.8K341.2K901.1K846.3K
Long-term debt1.04M0702.6K
Total debt4.77M569.9K136.1K276.0K393.4K734.4K
Total liabilities25.8M20.5M9.59M4.88M1.75M1.58M686.8K341.2K901.1K846.3K
Shareholders' equity-25.1M-13.0M12.5M47.6M28.1M4.14M4.88M3.26M3.65M5.38M
Shares outstanding328.3M307.0M303.3M273.6M245.5M197.3M175.9M159.5M158.2M148.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-10.9M-18.9M-30.3M-14.4M-6.84M-3.94M-4.19M-3.92M-2.74M-2.55M
Capital spending-3-3-99.3K-329.0K-17.2K-1.01M-24.0K-115.0K-251.7K-19.4K
Free cash flow-10.9M-18.9M-30.4M-14.8M-6.86M-4.94M-4.22M-4.03M-2.99M-2.57M
Cash from investing25.0K11.1M34.8M-46.3M-228.8K994.4K-1.02M-110.7K-551.7K1.93M
Cash from financing5.14M5.07M503.5K36.7M31.0M5.10M5.27M3.14M720.1K5.61M
Share buybacks248.6K4.98M036.5M29.9M3.56M4.73M2.81M470.5K255.1K
Change in cash-5.75M-2.71M4.95M-24.1M23.9M2.15M57.8K-888.2K-2.57M4.99M

Open Financials

Cap table

Built by 6ix from Sernova Biotherapeutics Inc’s releases · as of Oct 5, 2026

Common shares
377,642,509
Fully diluted
383,108,759

Fully diluted

LineSharesAs of
Common shares377,642,509
Warrants5,466,250Nov 13, 2025

Warrants and options

Lot
Warrants · C$0.25 · expire about Apr 2029
Warrants · C$0.40 · expire about Nov 2028
Warrants · C$0.20 · expiry not stated

Share count over time

CountShares
Nov 22, 2026377,642,509

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Steven Sangha
Director of Issuer
Placement26,666,667CAD 0.15CAD 4MApr 16, 2026
Jonathan M N Rigby
Director of Issuer
Placement229,877CAD 0.19CAD 43,677Apr 14, 2026
James T CPA Parsons
Director of Issuer
Placement229,877CAD 0.19CAD 43,677Apr 14, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bernd MuehlenwegDirector · Since at least Apr 9, 2026
David BurkeVice President, Investor Relations · Since at least Oct 5, 2026
David PatersonDirector · Since at least Apr 9, 2026
James ParsonsChief Financial Officer · Since at least Oct 5, 2026
John L. BrooksChair · Since at least Sep 23, 2025
Jonathan RigbyChief Executive Officer · Since at least Jun 2, 2025
Marie KaldchibachiDirector, Finance · Since at least Nov 5, 2026
Marylyn RigbyChief Communications Officer · Since at least Oct 5, 2026
Patricia BeastonChief Medical Officer · Since at least Oct 19, 2026
Steven SanghaDirector · Since at least Oct 5, 2026
All 11 people
PersonSeat
Tanya LewisDirector · Since at least Apr 9, 2026

Open People

Log in to ask 6ix AI your own questions about Sernova Biotherapeutics Inc.